This Founder Is Taking a Bite Out of the $50 Billion GLP-1 Market By Going Natural

This Founder Is Taking a Bite Out of the $50 Billion GLP-1 Market By Going Natural This Founder Is Taking a Bite Out of the $50 Billion GLP-1 Market By Going Natural

As pharmaceutical companies race to scale synthetic GLP-1s, Evolv is betting that consumers want a natural, orally available version.

Add a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Keep Up to Date with our Weekly Newsletter

By pressing the Subscribe button, you confirm that you have read and are agreeing to our Privacy Policy and Terms of Use
Advertisement